Browse > Article
http://dx.doi.org/10.5762/KAIS.2013.14.11.5809

Development of Technology Portfolio Analysis method for Technology-outsourcing of Pharmaceutical cooperations  

Hong, Sukchul (Department of Management of Technology, Sungkyunkwan University)
Publication Information
Journal of the Korea Academia-Industrial cooperation Society / v.14, no.11, 2013 , pp. 5809-5818 More about this Journal
Abstract
This study proposes a technology portfolio analysis method for technology outsourcing of pharmaceutical cooperations by applying the concepts of 'Pipeline Soundness' and 'Patent Validity'. This study also applied the developed portfolio analysis method to a 'real world case' of Amgen's acquisition of Onyx Pharmaceuticals to prove the applicability of the method to the real world cases and investigated the validity of the acquisition affair between the two companies. The results of portfolio analysis showed that Amgen's technology portfolio will be improved by acquiring Onyx Pharmaceuticals especially in cancer field which is their main field. So we concluded that Amgen's choice of Onyx pharmaceuticals as a source of technology outsourcing was reasonable. We think that the technology portfolio analysis method developed by this study will be a valuable tool for pharmaceutical cooperations for investigating their current technology status and selecting target companies for technology outsourcing.
Keywords
Patent analysis; Pharmaceutical industry; Pipeline analysis; Portfolio analysis; Technology outsourcing;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Anne Marie Clark, Heidi Berven. The face of the patent is not the "Whole Story" : determining the effective life of a pharmaceutical patent in the United States. World Patent Information. 26. 283-295. 2004. Available from: http://www.sciencedirect.com/science/article/pii/S017221 9004000675 DOI: http://dx.doi.org/10.1016/j.wpi.2004.04.010   DOI   ScienceOn
2 Henry G. Grabowski. John M. Vernon. Effective patent life in pharmaceuticals. Int. J. Technology Management. 19. 98-120. 2000. Available from: http://inderscience.metapress.com/content/fg1begfe6rxh8vx7/   DOI   ScienceOn
3 John A. Pearce II. How companies can preserve market dominance after patents expire. Long Range Planning. 39. 71-87. 2006. Available from: http://www.sciencedirect.com/science/article/pii/S0024630105000592 DOI: http://dx.doi.org/10.1016/j.lrp.2005.04.006   DOI   ScienceOn
4 Ronald J. Vogel. Pharmaceutical Patents and Price Controls, Clinical Therapeutics, 24(7), 1204-1222, 2002. Available from: http://www.sciencedirect.com/science/article/pii/S0024630105000592 DOI: http://dx.doi.org/10.1016/S0149-2918(02)80031-5   DOI   ScienceOn
5 Munos, B. "Lessons from 60 years of pharmaceutical innovation." Nat. Rev. Drug Discov.. 8, p.959-968, 2009. Available from: http://www.nature.com/nrd/journal/v8/n12/full/nrd2961.html DOI: http://dx.doi.org/10.1038/nrd2961   DOI   ScienceOn
6 Chesbrough, H.W. Open innovation: The new imperative for creating and profiting from technology, Boston, Harvard Business School Press, 2003. Available from: http://www.sciencedirect.com/science/article/pii/S0304405X05001807
7 Mathew J. Higgins, Daniel Rodriguez. The outsourcing of R&D through acquisitions in the pharmaceutical industry. Journal of Financial Economics. 80, p351-383, 2006. Available from: http://www.sciencedirect.com/science/article/pii/S030440 5X05001807 DOI: http://dx.doi.org/10.1016/j.jfineco.2005.04.004   DOI   ScienceOn
8 Danzon, P., Epstein, A., Nicholson, S., Mergers and acquisitions in the pharmaceutical and biotech industries. NBER Working Paper Series, Paper 10536.Available from: http:// www.nber.org/papers/w10536
9 Bernd Fabry, Holger Ernst, Jens Langholz, Martin Koster. Patent portfolio analysis as a useful tool for identifying R&D and business opportunities-an empirical application in the nutrition and health industry. World Patent Information. 28. 215-225, 2006. Available from: http://www.sciencedirect.com/science/article/pii/S0172219005001407 DOI: http://dx.doi.org/10.1016/j.wpi.2005.10.004   DOI   ScienceOn
10 Anthony Breizman, Patrick Thomas. "Using patent citation analysis to target/value M&A candidates.", Research Technology Management, pp.28-36, 2002. Available from: http/www.ngentaconnect.com contentiri/tm/2002 00000045 00000005art00006
11 Chih-Ping Wei, Yu-Syun Jiang, and Chin-Sheng Yang. "Patent analysis for supporting Merger and acquisition(M&A) prediction: A data mining approach", Lecture notes in business information processing. 22. p.187-200, 2009. Available from: http:/link.springer.comchapter10.1007978-3-642-01256-3_16# DOI: http://dx.doi.org/10.1007/978-3-642-01256-3_16   DOI
12 Kriegerm D., Ruback, R.S. Merck & company: evaluating a drug licensing opportunity. Harvard Business School Case #9-201-023. Available from: http:/www.hbs.edu/faculty Pages/ tem.aspx?num=27606
13 Steven M. Paul, Daniel S. Mytelka, Christopher T. Dunwiddie, Charles C. Persinger, Bernard H. Munos, Stacy R. Lindborg, Aaron L. Schacht. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature reviews. 9. 203-214. 2010. Available from: http://www.nature.com/nrd/journal/v9/n3/full/nrd3078.html
14 Holger Ernst. Patent portfolio for strategic R&D planning. J. Eng. Technol. Manage. 15. 279-308, 1998. Available from: http: // www.sciencedirect.com/ science/article/pii/S0923474898000186 DOI: http://dx.doi.org/10.1016/S0923-4748(98)00018-6   DOI   ScienceOn
15 Gudrun Littmann-Hilmer, Michael Kuckartz. SME tailor-designed patent portfolio analysis. World Patent information. 31. 273-277. 2009. Available from: http://www.sciencedirect.com/science/article/pii/S0172219008001762 DOI: http://dx.doi.org/10.1016/j.wpi.2008.12.003   DOI   ScienceOn